Zusammenfassung
Der Morbus Behçet (MB) ist eine Systemerkrankung mit dem histopathologischen Korrelat einer leukozytoklastischen Vaskulitis. Die Klassifikationskriterien der Erkrankung beinhalten das Vorhandensein oraler Aphthen in Kombination mit mindestens 2 weiteren Organmanifestationen wie genitale Aphthen, Hautmanifestationen oder einer Augenbeteiligung. Als pathognomonisch kann ein positives Ergebnis des Pathergietests gewertet werden. Die Prognose des MB ist immer dann ungünstig, wenn lebenswichtige Organe mitbetroffen sind. Dies gilt v. a. für die in ca. 10% auftretende Beteiligung des zentralen Nervensystems, die arteriellen und pulmonalarteriellen Aneurysmata sowie die gastrointestinale Beteiligung. Differenzialdiagnostische Schwierigkeiten bereitet v. a. die in ca. 50% vorhandene Oligoarthritis. Der MB ist in 50–80% der Fälle mit HLA-B51 assoziiert. Eine besonders ungünstige Prognose besteht immer dann, wenn die Erkrankung sich bereits bei relativ jungen Männern erstmanifestiert. Die Therapie der extraokulären Manifestationen richtet sich nach deren Aggressivität. So werden leichtere Manifestationen der Erkrankung mit niedrig dosiertem Prednisolon und steroidsparenden Immunsuppressiva wie Azathioprin oder Cyclosporin A behandelt, bei schwereren Manifestationen, wie z. B. der ZNS Beteiligung, kommen auch Cyclophosphamid oder TNF-Antagonisten, in ausgewählten Fällen auch Interferon-α in Betracht.
Abstract
Behcet’s disease is a multisystem disorder with the histopathological correlate of leukocytoclastic vasculitis. The classification criteria for the disease include the presence of recurrent oral aphthous ulcers combined with at least two other manifestations, such as genital aphthous ulcers, skin manifestations (mostly erythema nodosa or pseudofolliculitis) and ocular manifestations (panuveitis or posterior uveitis with retinal vasculitis). A positive pathergy test is regarded as pathognomonic for the disease and a sterile papulopustule occurs after a sterile needle prick of the forearm. However, this test is positive in only 15% of the patients. The prognosis of Behcet’s disease becomes unfavorable when vital organs are involved. This is the case for involvement of the central nervous system which occurs in 10% of patients, arterial and pulmonary arterial aneurysms and gastrointestinal involvement, which clinically and histopathologically is difficult to differentiate from inflammatory bowel disease but tends to perforate. Oligoarthritis, which occurs in approximately 50% of the patients, causes problems concerning the differential diagnosis from classical forms of spondyloarthritis. Behcet’s disease is associated with HLA-B51 in 50–80% of the cases depending on the country of origin of the patient. The prognosis becomes unfavorable if the disease manifests in young male patients. The treatment of extraocular manifestations depends on the aggressiveness. Milder manifestations are treated with low dose prednisolone and steroid sparing immunosuppressants, such as azathioprine or cyclosporine A. In cases with more severe manifestations, such as central nervous system (CNS) involvement cyclophosphamide or TNF antagonists and in selected cases also interferon alpha can be considered.
Literatur
Behcet H (1937) Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157
Adamantiades B (1930) A case of relapsing iritis with hypopion (in Greek). Archia Iatrikis Etairas (Proceedings of hte Medical Society of Athens) 586–539
Chun SI, Su WP, Lee S (1990) Histopathologic study of cutaneous lesions in Behcet’s syndrome. J Dermatol 17:333–341
Bang D, Hur W, Lee ES, Lee S (1995) Prognosis and clinical relevance of recurrent oral ulceration in Behcet’s disease. J Dermatol 22:926–929
McCarty MA, Garton RA, Jorizzo JL (2003) Complex aphthosis and Behcet’s disease. Dermatol Clin 21:41–48, vi
Ergun T, Gurbuz O, Dogusoy G et al (1998) Histopathologic features of the spontaneous pustular lesions of Behcet’s syndrome. Int J Dermatol 37:194–196
Hatemi G, Bahar H, Uysal S et al (2004) The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 63:1450–1452
Krause I, Molad Y, Mitrani M, Weinberger A (2000) Pathergy reaction in Behcet’s disease: lack of correlation with mucocutaneous manifestations and systemic disease expression. Clin Exp Rheumatol 18:71–74
Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105
Demirkesen C, Tuzuner N, Mat C et al (2001) Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol 116:341–346
Moll JM, Haslock I, Macrae IF, Wright V (1974) Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore) 53:343–364
Yurdakul S, Yazici H, Tuzun Y et al (1983) The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis 42:505–515
Takeuchi A, Mori M, Hashimoto A (1984) Radiographic abnormalities in patients with Behcet’s disease. Clin Exp Rheumatol 2:259–262
Hatemi G, Fresko I, Tascilar K, Yazici H (2008) Increased enthesopathy among Behcet’s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 58:1539–1545
Espinosa G, Font J, Tassies D et al (2002) Vascular involvement in Behcet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112:37–43
Leiba M, Sidi Y, Gur H et al (2001) Behcet’s disease and thrombophilia. Ann Rheum Dis 60:1081–1085
Hamuryudan V, Er T, Seyahi E et al (2004) Pulmonary artery aneurysms in Behcet syndrome. Am J Med 117:867–870
Yazawa S, Ishihara A, Kawasaki S (2001) Fatal thoracic aortic aneurysm in a patient with childhood-onset vasculo-Behcet’s disease: an autopsy report. Intern Med 40:1154–1157
Kasahara Y, Tanaka S, Nishino M et al (1981) Intestinal involvement in Behcet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 24:103–106
Al-Araji A, Kidd DP (2009) Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8:192–204
Siva A, Saip S (2009) The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol 256:513–529
Horger M, Maksimovic O, Kotter I, Ernemann U (2008) Neuro-Behcet’s disease: MR-imaging findings. Rofo 180:691–697
Hirohata S (2008) Histopathology of central nervous system lesions in Behcet’s disease. J Neurol Sci 267:41–47
Worthmann F, Bruns J, Turker T, Gosztonyi G (1996) Muscular involvement in Behcet’s disease: case report and review of the literature. Neuromuscul Disord 6:247–253
Cevik C, Otahbachi M, Nugent K, Jenkins LA (2009) Coronary artery aneurysms in Behcet’s disease. Cardiovasc Revasc Med 10:128–129
Lee I, Park S, Hwang I et al (2008) Cardiac Behcet disease presenting as aortic valvulitis/aortitis or right heart inflammatory mass: a clinicopathologic study of 12 cases. Am J Surg Pathol 32:390–398
Kotter I, Deuter C, Gunaydin I, Zierhut M (2006) MAGIC or not MAGIC – does the MAGIC (mouth and genital ulcers with inflamed cartilage) syndrome really exist? A case report and review of the literature. Clin Exp Rheumatol 24:108–112
Kotter I (2006) The magic of syndromes. Clin Exp Rheumatol 24:56–57
Khalid U, Saleem T (2011) Hughes-Stovin syndrome. Orphanet J Rare Dis 6:15
International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656–1662
Kotter I, Gunaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A (CSA) than under other medications – results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486
O’Duffy JD, Robertson DM, Goldstein NP (1984) Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med 76:75–84
Gul A, Tugal-Tutkun I, Dinarello CA et al (2011) Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71:563–566
Shapiro LS, Farrell J, Borhani Haghighi A (2011) Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clin Neurol Neurosurg 114(3):297–298
Hirano T, Ohguro N, Hohki S et al (2012) A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22(2):298–302
Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76
Sakamoto M, Akazawa K, Nishioka Y (1995) Prognostic factors of vision in patients with Behcet disease. Ophthalmology 102:317–321
Ando K, Fujino Y, Hijikata K et al (1999) Epidemiological features and visual prognosis of Behcet’s disease. Jpn J Ophthalmol 43:312–317
Dilsen N (2003) The importance of the manifestations besides the ones included in international criteria for Behcet’s disease. Adv Exp Med Biol 528:105–108
Kotter I (2009) EULAR recommendations for the management of Behcet’s disease: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Z Rheumatol 68:157–161
Interessenkonflikt
Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehungen hin: Vorträge, Grants, Beraterverträge Abbott, BMS, Roche, Novartis, Pfizer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kötter, I., Xenitidis, T., Fierlbeck, G. et al. Extraokuläre Manifestationen des Morbus Behçet. Ophthalmologe 109, 548–557 (2012). https://doi.org/10.1007/s00347-011-2502-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-011-2502-y